Development of stem cell-derived, islet replacement for type 1 diabetes
Kevin D’Amour1.
1ViaCyte Inc, San Diego, CA, United States
ViaCyte Inc. is a clinical stage company developing a stem cell-based islet replacement therapy for treatment of patients with diabetes. The therapy is a combination product comprised of pancreatic endoderm cells encapsulated within a retrievable delivery device. After implantation, progenitor cells differentiate into glucose-responsive, insulin-secreting cells. The renewable starting material for cell product manufacturing is human embryonic stem cells that are directed to differentiate to the pancreatic endoderm cell product using scalable processes. The bio-stable delivery device is designed to contain cells and facilitate formulation and delivery of the product to subcutaneous tissue sites.
Funding in part from California Institute for Regenerative Medicine and JDRF..
